BEYOND BIO
Daejeon, South Korea · Founded 2013
- Headquarters
- Daejeon
- Employees
- 1–10
- Founded
- 2013
- Business Model
- B2B
- Website
- beyondbio.co.kr
- Last Round
- Venture Round
- Rounds
- 1
About
BeyondBio Inc. is a South Korean biopharmaceutical company founded in 2013 and headquartered in Daejeon, specializing in the R&D of first-in-class small molecule drugs for diseases with high unmet medical needs. The company's pipeline targets pancreatic cancer, colorectal cancer, glioblastoma, blood cancer, lung cancer, and Alzheimer's disease, with lead candidates including BEY1107 (anticancer) and BEY2153, a novel dual-targeting anti-Alzheimer's drug candidate addressing both amyloid and tau proteins. BeyondBio has raised approximately $14.5M and aims to develop innovative therapies that overcome limitations of existing treatments.
Summary
BEYOND BIO is a Biotech company based in Daejeon, South Korea, founded in 2013. Investors include KB Investment.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Unknown
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company